Skip to main content
Equibles
INTS logo

INTS · Intensity Therapeutics, Inc. · Financials

Track INTS — free

Use INTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.04 +0.02 (+0.50%) At close · Sep 10
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the cash and cash equivalents as of June 30, 2026, the Company's ability to continue its operations thereafter is dependent on obtaining additional capital, which is not within the Company's control. As a result, the Company believes there is substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$13.19M
Shares
3.26M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Net Income
-$11.61M +28.7%
FY2025 Net Income FY2022–FY2025
Diluted EPS
-$8.56 +70.7%
FY2025 Diluted EPS FY2022–FY2025
Operating Cash Flow
-$9.23M +39.3%
FY2025 Operating Cash Flow FY2022–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2025 FY2024 FY2023 FY2022
$6.08M $6.79M $10.5M $4.79M $5.13M
$5.4M $5.19M $6.09M $3.53M $2.42M
$11.48M $11.97M $16.59M $8.32M $7.55M
-$11.48M -$11.97M -$16.59M -$8.32M -$7.55M
— — $0 $305K $82K
$319K $180K $314K $324K $2000
$1000 $186K $3000 — —
— $0 $0 $0 $0
-$11.16M -$11.61M -$16.27M -$10.54M -$7.58M
USD/shares -$1.76 -$8.56 -$29.24 -$34.50 -$55.50
USD/shares -$1.76 -$8.56 -$29.24 -$34.50 -$55.50
shares — 1.36M 556.28K 344.65K 136.4K
shares — 1.36M 556.28K 344.65K 136.4K
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 2.56×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.82×

Peer medians compare against the 227 similar-size Biotechnology companies (of 537 listed).

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023
Reportable Segment -$11,972,000 -$16,585,000 -$8,319,000
Key facts CIK 1567264 CUSIP 45828J202 13F (30d) 11 filings 10 filers Visit website Investor relations